Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Hypertension Research
  • View all journals
  • Search
  • Log in
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. hypertension research
  3. original article
  4. article
Effect of Olmesartan on Oxidative Stress in Hemodialysis Patients
Download PDF
Download PDF
  • Original Article
  • Published: 01 May 2007

Effect of Olmesartan on Oxidative Stress in Hemodialysis Patients

  • Daisuke Kadowaki1,
  • Makoto Anraku1,
  • Yuka Tasaki1,
  • Kenichiro Kitamura2,
  • Shiho Wakamatsu2,
  • Kimio Tomita2,
  • Janusz M Gebicki3,
  • Toru Maruyama1 &
  • …
  • Masaki Otagiri1 

Hypertension Research volume 30, pages 395–402 (2007)Cite this article

  • 1428 Accesses

  • Metrics details

Abstract

The effect of olmesartan, an inverse angiotensin II type 1 receptor blocker (ARB), on oxidative stress in hemodialysis (HD) patients is not fully understood, and has not been widely investigated in vitro or in vivo. We determined the amount of oxidized albumin and albumin hydroperoxides formed during incubation in the absence and presence of olmesartan by high-performance liquid chromatography (HPLC) and by a ferrous oxidation xylenol assay in an in vitro study. Six hypertensive HD patients were treated with 40 mg of olmesartan once daily, and blood pressure monitoring (BPM) was performed after 0, 4, and 8 weeks of treatment. The ratio of oxidized to unoxidized albumin was also determined. The oxidized albumin ratios and levels of albumin hydroperoxides were significantly decreased in a concentration-dependent manner in the presence of olmesartan, compared with the absence of olmesartan (p<0.05) in in vitro studies. In HD patients, olmesartan also significantly reduced systolic and diastolic blood pressure after 4 weeks, with a further significant decrease after 8 weeks. The ratio of oxidized to unoxidized albumin was markedly decreased after 4 weeks and these lower levels were maintained at 8 weeks. Olmesartan effectively lowered the extent of oxidation of albumin in both in vitro and in vivo studies, and this effect might confer benefits beyond a reduction in blood pressure.

Similar content being viewed by others

Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension

Article Open access 14 July 2025

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study

Article Open access 17 June 2025

Blood pressure control, hypertension phenotypes, and albuminuria: outcomes of the comprehensive Basel Postpartum Hypertension Registry

Article Open access 25 April 2025

Article PDF

References

  1. Suzuki H : Treatment of hypertension in chronic renal insufficiency. Intern Med 2000; 39: 773–777.

    Article  CAS  Google Scholar 

  2. Suzuki H : Angiotensin type 1 receptor blockers in chronic kidney disease. Contrib Nephrol 2004; 143: 159–166.

    Article  Google Scholar 

  3. Okada K, Hirano T, Ran J, Adachi M : Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructosefed rats. Hypertens Res 2004; 27: 293–299.

    Article  CAS  Google Scholar 

  4. Mizuno M, Sada T, Kato M, Koike H : Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271–278.

    Article  CAS  Google Scholar 

  5. Martina B, Dieterle T, Sigle JP, Surber C, Battegay E : Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 2003; 99: 169–170.

    Article  Google Scholar 

  6. Koh KK, Ahn JY, Han SH, et al: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905–910.

    Article  CAS  Google Scholar 

  7. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.

    Article  CAS  Google Scholar 

  8. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J : Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266–1272.

    Article  CAS  Google Scholar 

  9. Tschudi MR, Mesaros S, Luscher TF, Malinski T : Direct in situ measurement of nitric oxide in mesenteric resistance arteries: increased decomposition by superoxide in hypertension. Hypertension 1996; 27: 32–35.

    Article  CAS  Google Scholar 

  10. Weiss D, Kools JJ, Taylor WR : Angiotensin II–induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice. Circulation 2001; 103: 448–454.

    Article  CAS  Google Scholar 

  11. Haller H, Viberti GC, Mimran A, et al: Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403–408.

    Article  CAS  Google Scholar 

  12. Yamaguchi K, Ura N, Murakami H, et al: Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle. Hypertens Res 2005; 28: 773–778.

    Article  CAS  Google Scholar 

  13. Izuhara Y, Nangaku M, Inagi R, et al: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631–3641.

    Article  CAS  Google Scholar 

  14. Yuan Z, Nimata M, Okabe TA, et al: Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol 2005; 289: H1147–H1152.

    Article  CAS  Google Scholar 

  15. Miyata T, van Ypersele de Strihou C, Ueda Y, et al: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478–2487.

    Article  CAS  Google Scholar 

  16. Anraku M, Kitamura K, Shinohara A, et al: Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004; 66: 841–848.

    Article  CAS  Google Scholar 

  17. Shimada H, Kitamura K, Anraku M, et al: Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res 2005; 28: 987–994.

    Article  CAS  Google Scholar 

  18. Mera K, Anraku M, Kitamura K, et al: Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 2005; 28: 973–980.

    Article  CAS  Google Scholar 

  19. Gay CA, Gebicki JM : Measurement of protein and lipid hydroperoxides in biological systems by the ferric-xylenol orange method. Anal Biochem 2003; 315: 29–35.

    Article  CAS  Google Scholar 

  20. Shacter E, Williams JA, Lim M, Levine RL : Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 1994; 17: 429–437.

    Article  CAS  Google Scholar 

  21. Descamps-Latscha B, Witko-Sarsat V : Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001; 59 ( Suppl 78): S108–S113.

    Article  Google Scholar 

  22. Daschner M, Lenhartz H, Botticher D, et al: Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996; 50: 1268–1272.

    Article  CAS  Google Scholar 

  23. Witko-Sarsat V, Gausson V, Nguyen AT, et al: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82–91.

    Article  CAS  Google Scholar 

  24. Witko-Sarsat V, Gausson V, Descamps-Latscha B : Are advanced oxidation protein products potential uremic toxins? Kidney Int 2003; 63 ( Suppl 84): S11–S14.

    Article  Google Scholar 

  25. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–1313.

    Article  CAS  Google Scholar 

  26. Odetti P, Garibaldi S, Gurreri G, Aragno I, Dapino D : Protein oxidation in hemodialysis and kidney transplantation. Metabolism 1996; 45: 1319–1322.

    Article  CAS  Google Scholar 

  27. Himmelfarb J, McMonagle E : Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358–363.

    Article  CAS  Google Scholar 

  28. Bourdon E, Loreau N, Blache D : Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 1999; 13: 233–244.

    Article  CAS  Google Scholar 

  29. Gebicki JM : Protein hydroperoxides as new reactive oxygen species. Redox Rep 1997; 3: 99–110.

    Article  CAS  Google Scholar 

  30. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M : The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005; 334: 1322–1338.

    Article  CAS  Google Scholar 

  31. Sogami M, Nagaoka S, Era S, Honda M, Noguchi K : Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 1984; 24: 96–103.

    Article  CAS  Google Scholar 

  32. Hayakawa A, Kuwata K, Era S, et al: Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B Biomed Sci Appl 1997; 698: 27–33.

    Article  CAS  Google Scholar 

  33. Sogami M, Era S, Nagaoka S, et al: High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. J Chromatogr 1985; 332: 19–27.

    Article  CAS  Google Scholar 

  34. Suzuki E, Yasuda K, Takeda N, et al: Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 1992; 18: 153–158.

    Article  CAS  Google Scholar 

  35. Soejima A, Kaneda F, Manno S, et al: Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kidney Dis 2002; 39: 1040–1046.

    Article  CAS  Google Scholar 

  36. Soriani M, Pietraforte D, Minetti M : Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 1994; 312: 180–188.

    Article  CAS  Google Scholar 

  37. Stamler JS, Simon DI, Osborne JA, et al: S-Nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 1992; 89: 444–448.

    Article  CAS  Google Scholar 

  38. Unger T, Culman J, Gohlke P : Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998; 16: S3–S9.

    Article  CAS  Google Scholar 

  39. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212–2216.

    Article  CAS  Google Scholar 

  40. Yao L, Kobori H, Rahman M, et al: Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 2004; 27: 493–500.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

    Daisuke Kadowaki, Makoto Anraku, Yuka Tasaki, Toru Maruyama & Masaki Otagiri

  2. Department of Nephrology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Kenichiro Kitamura, Shiho Wakamatsu & Kimio Tomita

  3. Department of Biological Sciences, Macquarie University, Sydney, Australia

    Janusz M Gebicki

Authors
  1. Daisuke Kadowaki
    View author publications

    Search author on:PubMed Google Scholar

  2. Makoto Anraku
    View author publications

    Search author on:PubMed Google Scholar

  3. Yuka Tasaki
    View author publications

    Search author on:PubMed Google Scholar

  4. Kenichiro Kitamura
    View author publications

    Search author on:PubMed Google Scholar

  5. Shiho Wakamatsu
    View author publications

    Search author on:PubMed Google Scholar

  6. Kimio Tomita
    View author publications

    Search author on:PubMed Google Scholar

  7. Janusz M Gebicki
    View author publications

    Search author on:PubMed Google Scholar

  8. Toru Maruyama
    View author publications

    Search author on:PubMed Google Scholar

  9. Masaki Otagiri
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Masaki Otagiri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kadowaki, D., Anraku, M., Tasaki, Y. et al. Effect of Olmesartan on Oxidative Stress in Hemodialysis Patients. Hypertens Res 30, 395–402 (2007). https://doi.org/10.1291/hypres.30.395

Download citation

  • Received: 10 October 2006

  • Accepted: 26 December 2006

  • Issue date: 01 May 2007

  • DOI: https://doi.org/10.1291/hypres.30.395

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • olmesartan
  • blood pressure
  • oxidative stress
  • hemodialysis
  • albumin

This article is cited by

  • Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury

    • Daisuke Kadowaki
    • Makoto Anraku
    • Masaki Otagiri

    Clinical and Experimental Nephrology (2015)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open Access Fees and Funding
  • Guide to Authors
  • About the Editors
  • Message from Editors
  • Call for Paper
  • Contact
  • About the Partner
  • For Advertisers
  • Subscribe
  • Showcase of Graphical Abstracts on Hypertension Research

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Hypertension Research (Hypertens Res)

ISSN 1348-4214 (online)

ISSN 0916-9636 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited